ASH 2022 | Phase Ib/II study of Viro-T-cell in patients with R/R CML infection after alloSCT
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, describes a study that assessed the use of Viro-T-cell, an academic allogeneic virus-specific T-cell (VST-cell) product in treating patients with cytomegalovirus (CMV) infection following allogeneic stem cell transplantation (alloSCT; NCT04018261). The study showed that Viro-T-cell was well tolerated and was effective in patients with relapsed/refractory (R/R) CMV infection. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Allogene, Amgen, BMS, Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar and Novartis: Consultancy.
